Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00090090 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 114
Last updated 2008-01-15
Summary
To determine the safety and efficacy of elsamitrucin in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). To determine if elsamitrucin is efficacious in a particular pathologic NHL subtype(s).
Conditions
- Mantle Cell Lymphoma
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Interventions
- DRUG
-
Elsamitrucin
Sponsors & Collaborators
-
Spectrum Pharmaceuticals, Inc
lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-04-30
- Completion
- 2006-10-31
Countries
- United States
Study Locations
More Related Trials
-
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT01955499 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
NCT00516217 ·Status: COMPLETED ·Phase: PHASE2
-
Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)
NCT05891821 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma
NCT02082977 ·Status: TERMINATED ·Phase: PHASE1
-
Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00550615 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
NCT01534715 ·Status: COMPLETED ·Phase: PHASE1
-
Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
NCT02824029 ·Status: COMPLETED ·Phase: PHASE2
-
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
NCT02568553 ·Status: COMPLETED ·Phase: PHASE1
-
Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma
NCT00359086 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma
NCT06561425 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
NCT01796470 ·Status: TERMINATED ·Phase: PHASE2
-
Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects
NCT02519270 ·Status: TERMINATED ·Phase: PHASE1
-
Aminocamptothecin in Treating Patients With Refractory or Recurrent Hodgkin's Disease or Non-Hodgkin's Lymphoma
NCT00002745 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment
NCT05014412 ·Status: COMPLETED ·Phase: PHASE2
-
Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma
NCT06088654 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
NCT01088048 ·Status: COMPLETED ·Phase: PHASE1
-
SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.
NCT05293912 ·Status: TERMINATED ·Phase: PHASE1
-
A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
NCT00452127 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma
NCT00868608 ·Status: COMPLETED ·Phase: PHASE2
-
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
NCT01567709 ·Status: COMPLETED ·Phase: PHASE1
-
Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT00989586 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
NCT05190068 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
NCT02309580 ·Status: COMPLETED ·Phase: PHASE1
-
An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma
NCT05315713 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study
NCT00837174 ·Status: WITHDRAWN ·Phase: PHASE2